Palisade Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference and Biotech Showcase
December 29 2021 - 8:30AM
Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage
biopharmaceutical company advancing therapies for acute and chronic
gastrointestinal (GI) complications, announces that they will
present at the H.C. Wainwright BIOCONNECT Virtual Conference taking
place January 10-13, 2022, and at Biotech Showcase taking place
January 10-12, 2022. The Palisade Bio management team also will be
hosting investor meetings during that period and talking about
their lead program, LB1148. LB1148 has shown significant results in
a Phase 2 trial with a 1.1-day improvement in return to bowel
function following GI surgery in the mean.
Details of the presentations are as follows:
Event: |
H.C.
Wainwright BIOCONNECT Virtual Conference |
Date: |
January 10-13, 2022 |
Time: |
Presentation available starting at 7:00 a.m., ET on January 10,
2022 |
|
|
Event: |
Biotech Showcase |
Date: |
January 10-12, 2022 |
Time: |
Presentation available starting at 8:00 a.m., PT on January 4,
2022 |
The presentations will be accessible in the
investor relations section of the Palisades Bio website here.
About Palisade Bio
Palisade Bio is a clinical stage biopharmaceutical company
advancing therapies that help patients with acute and chronic
gastrointestinal complications stemming from post-operative
digestive enzyme damage. Palisade Bio’s innovative lead asset
LB1148, advancing towards Phase 3, is a protease inhibitor with the
potential to both reduce abdominal adhesions and help restore bowel
function following surgery. Positive data from Phase 2 trials of
LB1148 demonstrated safety and tolerability as well as a
statistically significant improvement in return to bowel function
and decrease in length of stay in ICU and hospital compared to
placebo. Palisade Bio believes that its investigational therapies
have the potential to address the myriad health conditions and
complications associated with chronic disruption of the
gastrointestinal epithelial barrier. For more information, please
go to www.palisadebio.com.
Forward Looking StatementsThis communication
contains “forward-looking” statements, including, without
limitation, statements related to expectations regarding Palisade’s
plans for future presentations at investor conferences. Any
statements contained in this communication that are not statements
of historical fact may be deemed to be forward-looking statements.
These forward-looking statements are based upon Palisade’s current
expectations. Forward-looking statements involve risks and
uncertainties. Palisade’s actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, the Company’s
ability to advance its clinical programs and the uncertain and
time-consuming regulatory approval process. Additional risks and
uncertainties can be found in Palisade Bio’s Quarterly Report on
Form 10-Q for the quarter ended September 30,
2021. Palisade expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Palisade’s expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based.
Palisade Bio Investor Relations
Contact: Dawn
Hofmeisterir@palisadebio.comPalisade Bio Media Relations
Contact:CORE IRJules
Abrahamjulesa@coreir.com917-885-7378
Palisade Bio (NASDAQ:PALI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Palisade Bio (NASDAQ:PALI)
Historical Stock Chart
From Jul 2023 to Jul 2024